

B. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. *(currently amended)* A method of inhibitingtreating a T-cell mediated inflammation disorder in a subject in need thereofhaving low activity or no activity of runt-related transcription 3 factor (RUNX3) gene product, the method comprising contacting cells of the subject withdelivering an active agent that induces up-regulationexpression or over-expression of RUNX3 expression into the immune cells of said subject, thereby inhibiting the proliferation of T-cells.
2. *(currently amended)* The method of claim 1 wherein the immune cells are selected from the group consisting of thymocytes and dendritic cells (DC).
3. *(currently amended)* The method of claim 2 wherein the immune cells of the subject are dendritic cells.
4. *(previously presented)* The method of claim 3 wherein the active agent reduces the proportion of mature dendritic cells versus immature dendritic cells in said subject.
5. *(previously presented)* The method of claim 4, wherein the reduction in the proportion of mature dendritic cells versus immature dendritic cells is determined by a reduction in the proportion of dendritic cells expressing CD80, CD86, MHC class II and OX40L.
6. *(previously presented)* The method of claim 1, wherein the active agent comprises a polynucleotide encoding Runx3 or a polynucleotide encoding a RUNX3 promoter activator.
7. *(previously presented)* The method of claim 6 wherein the polynucleotide further comprises a viral-based vector.

8. *(currently amended)* The method of claim 1 wherein the contact between the cells and the active agent delivery step is performed *ex vivo*.

9. *(currently amended)* The method of claim 1, wherein the subject suffers from a T-cell mediated inflammation disorder is selected from the group consisting of a chronic inflammatory disease, a T cell-mediated autoimmune disease and tissue transplantation asthma, allergic asthma, Crohn's disease, and ulcerative colitis.

10-12. *(canceled)*

13. *(currently amended)* A method of attenuating dendritic cell[[s]] maturation in a subject in need thereof having low activity or no activity of runt-related transcription 3 factor (RUNX3) gene product, the method comprising contacting delivering dendritic cells of the subject with an active agent that induces up regulation expression or over-expression of RUNX3 expression into the dendritic cells of said subject, thereby attenuating [[the]] dendritic cell[[s]] maturation in said subject.

14-48. *(canceled)*

* * * * *